Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter Phase II Trial of Oxaliplatin and Docetaxel for Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck.

Next Previous
X
Search
Trial Profile

Multicenter Phase II Trial of Oxaliplatin and Docetaxel for Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2013

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Docetaxel (Primary) ; Oxaliplatin (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Aug 2011 Planned End Date changed from 1 Dec 2010 to 1 Nov 2009 as reported by ClinicalTrials.gov.
    • 20 Jan 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 01 Jul 2009 Planned end date changed from 1 Mar 2009 to 1 Dec 2010 as reported by ClinicalTrials.gov,

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top